USE IN DIVERSE
PEOPLE LIVING
WITH HIV

Diversity of people living with HIV

VOCABRIA + REKAMBYS has been studied in broad and diverse populations of people living with HIV[1]

>39,000 people living with HIV have received VOCABRIA + REKAMBYS in real-world cohorts*[1]

VOCABRIA + REKAMBYS has been studied across diverse populations to demonstrate its ability to help meet diverse needs of people living with HIV.[1]

*Potential overlap between real-world cohorts cannot be ruled out.[1]
†Consider patient BMI to see if a longer needle could be needed; a post hoc analysis of participants in phase III trials (FLAIR, ATLAS, ATLAS-2M) showed that a combination of at least two of the following baseline factors may be associated with an increased risk of CVF: archived RPV RAMs, HIV-subtype A6/A1, and BMI ≥30 kg/m2. In patients with an incomplete or uncertain treatment history without pretreatment resistance analyses, caution is warranted in the presence of either BMI ≥30 kg/m2 or HIV-1 A6/A1 subtype.[5–7]

Discover the impact of VOCABRIA + REKAMBYS in diverse real-world populations

Explore

A Patient Testimonial: Agatha's Story

UK patient testimonial looking at the experience of Agatha, a person living with HIV, the challenges she faces and what she believes we can do to improve patient experience.

A Patient Testimonial: Angelina's Story

Angelina, a person living with HIV, shares her experience on VOCABRIA + REKAMBYS to help us to understand different perspectives on treatment.

Are you offering VOCABRIA + REKAMBYS to eligible patients?

Learn about the importance of shared decision making for patient care

Learn more

Contact us for support

ART=antiretroviral therapy; BMI=body mass index; CVF=confirmed virologic failure; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; RAM=resistance-associated mutation; RPV=rilpivirine.

References:

  1. Data on File. Number of people with HIV that have received VOCABRIA + REKAMBYS in clinical trials and real-world studies. March 2026. REF-314506. ViiV Healthcare group of companies.
  2. Lazarus JV, Safreed-Harmon K, Kamarulzaman A, et al. Consensus statement on the role of health systems in advancing the long-term well-being of people with HIV. Nat Commun. 2021;12(1):4450. doi: 10.1038/s41467-021-24673-w. 
  3. UK Health Security Agency. Positive Voices 2022 Survey Report. January 2024. Available at: https://www.gov.uk/government/publications/hivpositive-voices-survey/positive-voices-2022-survey-report. Accessed March 2026.
  4. UNAIDS. 2025 AIDS Targets. Available at: https://aidstargets2025.unaids.org/. Accessed March 2026.
  5. VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC).
  6. REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC).
  7. Orkin C, Schapiro J, Perno C, et al. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated with Virologic Failure. Clinical Infect Dis. 2023;77(10):1423-1431. doi: 10.1093/cid/ciad370.

REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.

PM-GB-CBR-WCNT-250009 | March 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.